智通财经APP讯，东诚药业(002675.SZ)公告，公司控股子公司烟台蓝纳成生物技术股份有限公司(简称“蓝纳成”)正在研发的氟[18F]思睿肽注射液是一种靶向PSMA的放射性体内诊断药物，适用于下述前列腺癌患者前列腺特异性膜抗原(PSMA)阳性病灶的正电子发射断层扫描(PET)成像：拟接受初始根治性治疗，怀疑存在转移灶的前列腺癌患者;血清前列腺特异性抗原(PSA)水平升高，怀疑生化复发的前列腺癌患者。
更多港股重磅资讯，下载智通财经app
更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.